Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYPLA1 | O75608 | 1/20 | 0.55 |
| ▸ | LYPLA2 | O95372 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 7/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12271226 | 0.95 | LYPLA1 (0.51) | LYPLA1LYPLA2MAOBCACNA1BSLC6A5 | |
| SCHEMBL2407885 | 0.87 | LYPLA1 (0.54) | LYPLA1LYPLA2CACNA1BHRH3 | |
| SCHEMBL12266345 | 0.84 | LYPLA1 (0.77) | LYPLA1LYPLA2HRH3KEAP1NFE2L2 | |
| SCHEMBL12266259 | 0.83 | MAOB (0.62) | MAOBHRH3HMOX1 | |
| SCHEMBL16151506 | 0.82 | MAOB (0.51) | MAOBCACNA1BSLC6A5FFAR1PPARG | |
| SCHEMBL12270408 | 0.81 | LYPLA1 (0.49) | LYPLA1LYPLA2CACNA1BHRH3 | |
| SCHEMBL12270826 | 0.81 | MAOB (0.55) | MAOBFFAR1PPARG | |
| SCHEMBL12271043 | 0.79 | MAOB (0.47) | MAOBCACNA1BSLC6A5FFAR1PPARG | |
| SCHEMBL12270360 | 0.76 | LYPLA1 (0.51) | LYPLA1LYPLA2MAOBCACNA1BHRH3 | |
| SCHEMBL12266256 | 0.74 | MAOB (0.64) | MAOBHRH3FFAR1PPARGHMOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | LYPLA1 1153/4885LYPLA2 1988/4885MAOB 627/4885 |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | KCNMB4, CA2, NR0B2 | LYPLA1 4548/4885LYPLA2 4342/4885MAOB 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.